Company intelligence / Profile preview

Primary Bioscience

Seattle, Washington, United Statesprimarybioscience.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Primary Bioscience is developing a single molecule protein sequencing device aimed at enabling unbiased, comprehensive analysis of every protein in a sample. The platform is designed to detect hard-to-identify variations such as single residue substitutions, splice variants, and post-translational truncations. No clinical results are available as the product appears to be pre-commercialization[1][2].

Therapeutic areas: Other
Modalities: Protein sequencing technology (not a therapeutic modality, but a platform for biomarker/protein analysis)
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on Primary Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Primary Bioscience.

Explore the full profile